Table 1 Patients' characteristics
From: BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors
Sex | |||
|---|---|---|---|
| Â | Male | 21 | (60%) |
| Â | Female | 14 | (40%) |
Age, years | |||
| Â | Median | 53 | Â |
| Â | Range | 27-77 | Â |
| Â | < = 45 | 9 | (26%) |
| Â | > 45 | 27 | (74%) |
Tumor burden (product of largest cross-sectional diameters), mm2 | |||
| Â | Median | 736 | Â |
| Â | Range | 20-3519 | Â |
| Â | Not measurable | n = 8 | (23%) |
KPS | |||
| Â | Median | 70 | Â |
| Â | Range | 40-90 | Â |
| Â | 90 | 7 | (20%) |
| Â | 70-80 | 15 | (43%) |
| Â | <70 | 13 | (37%) |
Time from diagnosis to start of BCNU, weeks | |||
| Â | Median | 38 weeks | Â |
| Â | Range | 11-189 weeks | Â |
Primary therapy | |||
| Â | Total resection | 15 | (43%) |
| Â | Partial resection | 4 | (11%) |
| Â | Biopsy | 16 | (46%) |
| Â | Temozolomide | 24 | (71%) |
| Â | Radiation | 31 | (89%) |
Number of relapses at start of BCNU therapy | |||
| Â | First | 30 | (86%) |
| Â | Second | 4 | (11%) |
| Â | Third | 0 | (0%) |
| Â | Fourth | 1 | (3%) |